

Cover Story
Conversation with The Cancer LetterFree
After a decade of near-absence from the US market, the AstraZeneca drug Iressa (gefitinib) is back.
In Brief


Drugs & Targets
Trending Stories
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- In the Headlines: Is oncology ready to move away from animal testing?
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- Imaging’s ride to the bottom in clinical trials—and why it matters now
- Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya - Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out